Vaccines administered, autoimmune diagnoses, immunosuppressive regimens and perivaccination management with serial antispike antibody responses
| Age/sex | Diagnosis | Immunosuppression | Initial vaccine series | Meds held or modified preinitial Vaccine | Pre-AD1 antibody U/mL* | Additional vaccines | PostAD1 antibody U/mL* | PostAD2 antibody U/mL* | Therapy held periAD† |
| 62F | Myositis | Mycophenolate‡ Prednisone | Pfizer | No | Negative§ | AD1: Pfizer AD2: Pfizer | – | <0.4 | No |
| 56F | Mucous membrane pemphigoid | Mycophenolate‡ | Pfizer | No | <0.4 | AD1: J&J AD2: Moderna | <0.8 | <0.4 | No |
| 67F | Systemic sclerosis | Mycophenolate‡ | Pfizer | No | <0.4 | AD1: Pfizer AD2: Pfizer | <0.4 | 2.1 | Yes |
| 73M | Myasthenia gravis | Mycophenolate‡ Prednisone | Moderna | No | <0.4 | AD1: Pfizer AD2: Pfizer | – | 21.8 | – |
| 44F | Inflammatory arthritis¶ | Abatacept Hydroxychloroquine Methotrexate Prednisone | Pfizer | No | <0.4 | AD1:Pfizer AD2: J&J | <0.4 | 27.1 | Yes |
| 55M | Inflammatory arthritis¶ | Infliximab Mycophenolate‡ | Pfizer | No | Negative§ | AD1: Pfizer AD2: Pfizer | <0.8 | 46.5 | Yes |
| 64F | Myositis | Mycophenolate‡ | Pfizer | No | Negative§ | AD1: Pfizer AD2: Pfizer | 38.1 | 120.9 | Yes |
| 53F | Inflammatory arthritis¶ | Adalimumab Mycophenolate‡ Prednisone | Pfizer | No | <0.4 | AD1: Moderna AD2: Moderna | 229 | 134 | No |
| 55M | Sarcoidosis | Infliximab Mycophenolate‡ Prednisone | Pfizer | No | <0.4 | AD1: Moderna AD2: Moderna | 2.40 | 1276 | Yes |
| 40F | Inflammatory bowel disease | Adalimumab Hydroxychloroquine Methotrexate | Pfizer | No | 178.4 | AD1: Moderna AD2: Pfizer | 601.2 | 1750 | No |
| 49F | Overlap CT disease** | Belimumab Methotrexate Prednisone | Pfizer | No | <0.4 | AD1: Pfizer AD2: Pfizer | 16.4 | >2500 | – |
| 68F | Proliferative nephritis | Mycophenolate‡ Prednisone | Moderna | No | <0.4 | AD1: J&J AD2: Moderna | 714 | >2500 | – |
| 53F | Sjὅgren’s syndrome | Azathioprine | J&J | No | <0.4 | AD1: Pfizer AD2: Pfizer | >250 | >2500 | Yes |
| 55F | Minimal change disease | Mycophenolate‡ | J&J | No | <0.4 | AD1: Moderna AD2: Moderna | >2500 | >2500 | No |
| 74M | Myositis | Mycophenolate‡ | Pfizer | No | Negative§ | AD1: Moderna AD2: Moderna | >2500 | >2500 | Yes |
| 42F | Overlap CT disease** | Hydroxychloroquine Mycophenolate‡ | Pfizer | No | <0.4 | AD1: Pfizer AD2: Pfizer | – | >2500 | Yes |
| 65F | Inflammatory arthritis | Abatacept | J&J | No | Negative§ | AD1: Pfizer AD2: Pfizer | – | >2500 | Yes |
| 52M | Overlap CT disease** | Hydroxychloroquine Mycophenolate‡ | J&J | No | 18.6 | AD1: Pfizer AD2: Pfizer | >2500 | >2500 | Yes |
- denotes missing data.
*Roche Elecsys anti-RBD pan-Ig≥0.8 units/mL is considered positive (upper ceiling expanded from>250 to >2500 U/mL per manufacturer).
†Pre-AD1 median number of doses held for mycophenolate 6, 23 doses of azathioprine held by one patient, and two abatacept infusion held by one patient. Pre-AD2 median number (IQR) of doses of mycophenolate 14 (10–14), 23 doses of azathioprine and 2 abatacept infusion held by one patient.
‡Mycophenolate includes mycophenolic acid and mycophenolate mofetil.
§Self-reported values.
¶Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, or inflammatory bowel disease associated arthritis.
**Denotes a combination of two or more defined rheumatic diagnoses.
AD, additional dose; J&J, Johnson and Johnson; RBD, receptor binding domain.